St. Jude Medical (NYSE:STJ) and Thoratec (NSDQ:THOR) today confirmed that St. Jude agreed to acquire Thoratec for $3.4 billion. The terms of the deal call for St. Jude to pay $63.50 in cash for each share of Pleasanton, Calif.-based Thoratec, funded using term loans and senior unsecured debt, Little Canada, Minn.-based St. Jude said. Rumors about a possible […]
Thoratec Corp.
Report: St. Jude Medical in talks to acquire Thoratec
St. Jude Medical (NYSE:STJ) is reportedly in talks to acquire Thoratec (NSDQ:THOR), according to “people familiar with the situation.” Although the 2 companies are in ongoing discussions, no final deal has been agreed and the negotiations may still fall apart, the sources told Bloomberg. Thoratec could also opt to seek a different buyer, 1 of the people said. THOR shares rose […]
HeartWare launches European trial for next-gen MVAD heart pump
HeartWare International (NSDQ:HTWR) said today that it’s launching a clinical trial aimed at winning CE Mark approval in the European Union for its next-generation MVAD implantable heart pump. The prospective, non-randomized, single-arm study is slated to enroll 60 patients, who will be implanted with the MVAD pump via sternotomy or thoracotomy, with a primary endpoint of survival at 6 months, […]
Thoratec wins CE Mark for HeartMate PHP
Thoratec (NSDQ:THOR) said today it won CE Mark approval in the European Union for its HeartMate percutaneous heart pump. Approval was based on data from the 1st 30 patients enrolled in its Shield I CE mark trial, the Pleasanton, Calif.-based company said. Data from all 50 patients in the study is slated to be presented later this […]
Thoratec touts less-invasive HeartMate 3 implantation
Thoratec (NSDQ:THOR) yesterday revealed the 1st implantation of its next-generation HeartMate III implantable heart pump using a mini-thoracotomy approach. The implantation, part of a European trial designed to examine less-invasive procedures such as hemi-sternotomy and left thoracotomy, was the 1st of a planned 10 surgeries, Pleasanton, Calif.-based Thoratec said. “This achievement marks the latest step in our progress […]
Thoratec to go head-to-head with Abiomed’s Impella
A tale of 2 LVADs: Thoratec gains, HeartWare slides on Q1 results
ConvaTec makes interim chief Moraviec CEO | Personnel Moves
ConvaTec, which is rumored to be exploring a sale, said yesterday that it made its interim CEO, former EMEA president Paul Moraviec, to be its new permanent CEO.
Luxembourg-based ConvaTec, which is owned by private equity firms Avista Capital Partners and Nordic Capital, tapped Moraviec to lead its business in Europe, the Middle East and Africa in 2009.